Antibody-drug conjugate publication spotlight: Our top recent peer-reviewed journal articles featuring Fortrea oncologists discussing ADC drug development

Antibody-drug conjugates (ADCs) represent one of the largest growth segments in oncology, holding the promise of more effective therapies that can offer lower systemic toxicity, for better patient outcomes. With more than a dozen ADCs having received FDA approval so far, and approximately 200 more in the drug development pipeline, the global market for ADCs has topped $10B in recent years and is forecasted to continue to grow as this class of drugs develops and is applied to more clinical indications.

Fortrea supports our sponsors with a dedicated team of 50+ oncologists who take a collaborative approach to clinical research, which can result in co-authorship of peer reviewed journal articles based on projects we've supported. In addition, they have contributed to industry knowledge via articles about their own academic and collaborative work. We are proud that our oncology team contributes to the advancement of cancer research in this way. Some of our latest publications relating to ADCs include the following articles.



Fortrea

2023	
Number	**Authors, Title, Journal**
2023.1	Salifu I, Singh N, Berraondo M, Remon J, Salifu S, Severson E, Quintana A, Peiro S, Ramkissoon S, Vidal L, Chico I, Saini KS. **Antibody-drug conjugates, immune-checkpoint inhibitors and their combination in advanced non-small cell lung cancer.** *Cancer Treatment and Research Communications.* April 2023. https://doi.org/10.1016/j.ctarc.2023.100713 **Summary:** Antibody-drug conjugates have emerged as one of the most exciting advances in cancer therapeutics in the past decade and Fortrea has been involved in the execution of clinical trials for many such molecules. This manuscript highlights the growing role of ADCs in non-small cell lung cancer.
2023.2	Ko H, Previs RA, Strickland KC, Klein J, Caveney B, Chiruzzi C, Eisenburg M, Severson EA, Ramkissoon S, Saini KS. **Is HER2-low a new clinical entity or merely a biomarker for an antibody drug conjugate?** *Oncology & Therapy*. November 2023. https://doi.org/10.1007/s40487-023-00249-0 **Summary:** Fortrea oncologists make a nuanced analysis of the move from the conventional bimodal HER2 receptor status (HER2-positive and HER2-negative) to a trimodal by adding a new category of HER2-low.
2021	
Number	**Authors, Title, Journal**
2021.1	Saini KS, Punie K, Twelves C, Bortini S, de Azambuja E, Anderson S, Criscitiello C, Awada A, Loi S. **Antibody-drug conjugates, immune-checkpoint inhibitors and their combination in breast cancer therapeutics.** *Expert Opinion in Biologic Therapy*. June 2021. https://doi.org/10.1080/14712598.2021.1936494 **Summary:** In the recent years, breast cancer systemic therapy has been revolutionized by immunotherapy as well as ADCs targeting HER2, TROP2 and other targets.

See a full list of Fortrea oncology publications starting in 2020.

LEARN MORE at fortrea.com/oncology

Fortrea